Burton F. Dickey
Burton F. Dickey was born in New York in 1953, and received a B.S. degree from Columbia University summa cum laude, and a Medical degree from the University of Connecticut. He did residency training in internal medicine at Temple University Hospital in Philadelphia, and fellowship training in pulmonary and critical care medicine and in biochemistry at Boston University Medical Center. Currently, he serves as Chair of the Department of Medicine at the University of Texas MD Anderson Cancer Center, where he has a clinical practice focused on inflammatory diseases of the airways and pneumonia. His research is focused on airway epithelial cells, which show great plasticity in structure, function, and gene expression in response to inflammation. In allergic inflammation, airway secretory cells produce large quantities of polymeric mucins, and the laboratory studies the molecular mechanism of mucin secretion. Epithelial signaling by the beta-2-adrenoceptor promotes allergic inflammation and mucin production, and the laboratory is studying the molecular mechanism of this proinflammatory function. In response to TLR signaling, airway epithelial cells develop a high level of resistance to microbial infection, and the laboratory is studying the molecular mechanism of inducible resistance and developing a clinical therapeutic to prevent pneumonia. Airway inflammation also contributes to epithelial carcinogenesis, and the laboratory has established mouse models of this phenomenon and is dissecting its mechanism. For each of these programs, the laboratory uses primarily a mouse genetic approach, generating knockout and transgenic mice, and analyzing their responses in conditions of pathophysiologic challenge. Dr. Dickey serves as an Associate Editor of the British Journal of Pharmacology, and served as Cochair of the Keystone Symposium on Rab GTPases in 2004 and the Gordon Research Conference on Mucociliary Interactions in 2011.
Biography Updated on 25 November 2010